on OXURION (EBR:OXUR)
Oxurion Expands Clinical Research Capabilities with Strategic Partnership
Oxurion NV, a biopharmaceutical company in Leuven, Belgium, has announced a strategic partnership between its subsidiary Axiodis CRO and KYomed INNOV & CEISO, a French clinical CRO specializing in digital health and medical device research. This collaboration aims to enhance clinical data management and biometrics services.
This partnership addresses increasing industry demands by providing robust biometrics support from study design to statistical analysis. The collaboration allows Axiodis CRO to offer its specialist services, optimizing study design and strengthening data quality.
The partnership is expected to generate EUR 110,000 in annual revenue, with potential growth up to EUR 170,000. It supports Oxurion's strategy of integrating scientific services with technology-enabled operations to meet growing demands in clinical research.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news